![SciELO - Brasil - Marcadores moleculares no câncer de pulmão: papel prognóstico e sua relação com o tabagismo Marcadores moleculares no câncer de pulmão: papel prognóstico e sua relação com o tabagismo SciELO - Brasil - Marcadores moleculares no câncer de pulmão: papel prognóstico e sua relação com o tabagismo Marcadores moleculares no câncer de pulmão: papel prognóstico e sua relação com o tabagismo](https://minio.scielo.br/documentstore/1806-3756/QytwY3bdQmckM7Z8zPypmSP/2c61e75018d54ce51fb990b6b1124136d5f9df4e.gif)
SciELO - Brasil - Marcadores moleculares no câncer de pulmão: papel prognóstico e sua relação com o tabagismo Marcadores moleculares no câncer de pulmão: papel prognóstico e sua relação com o tabagismo
![PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer](https://www.researchgate.net/profile/Joachim-Pawel/publication/242354126/figure/tbl2/AS:393144983146497@1470744476106/Recommendations-for-use-of-markers-according-to-histologies-of-lung-cancer-and_Q320.jpg)
PDF) National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer
![Frontiers | Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities Frontiers | Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities](https://www.frontiersin.org/files/Articles/650293/fonc-11-650293-HTML/image_m/fonc-11-650293-t001.jpg)
Frontiers | Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities
Serum marker values (small cell lung cancer [SCLC] vs. non-small cell... | Download Scientific Diagram
![A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer - eBioMedicine A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer - eBioMedicine](https://www.thelancet.com/cms/asset/7cee8ea5-7859-42fa-9c45-9b933c1c7409/gr1.jpg)
A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer - eBioMedicine
![Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma - Chinese Journal of Cancer Research Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma - Chinese Journal of Cancer Research](http://www.cjcrcn.org/data/pic/3347_0.png)
Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma - Chinese Journal of Cancer Research
![Correlation between Expression of Metallothionein and Expression of Ki-67 and MCM-2 Proliferation Markers in Non-Small Cell Lung Cancer | Anticancer Research Correlation between Expression of Metallothionein and Expression of Ki-67 and MCM-2 Proliferation Markers in Non-Small Cell Lung Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/31/9/2833/F1.large.jpg)
Correlation between Expression of Metallothionein and Expression of Ki-67 and MCM-2 Proliferation Markers in Non-Small Cell Lung Cancer | Anticancer Research
![Silvija Gottesman MD on Twitter: "Dr Isaac Brownell: IHC markers to distinguish Merkel Cell Ca and Small Cell Lung Cancer and their limitations. #ASDP2017 #dermpath #lungpath https://t.co/KkV1K6TsXz" / Twitter Silvija Gottesman MD on Twitter: "Dr Isaac Brownell: IHC markers to distinguish Merkel Cell Ca and Small Cell Lung Cancer and their limitations. #ASDP2017 #dermpath #lungpath https://t.co/KkV1K6TsXz" / Twitter](https://pbs.twimg.com/media/DNLbdIAXUAAz7kR.jpg)
Silvija Gottesman MD on Twitter: "Dr Isaac Brownell: IHC markers to distinguish Merkel Cell Ca and Small Cell Lung Cancer and their limitations. #ASDP2017 #dermpath #lungpath https://t.co/KkV1K6TsXz" / Twitter
![Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. | Semantic Scholar Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e7db51474405e7a96dad81cbfdf41e7c623abdb9/4-Table2-1.png)
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. | Semantic Scholar
![Table 2 from SRSF 5 : a novel marker for small-cell lung cancer and pleural metastatic cancer Short title : SRSF 5 protein is a new SCLC marker | Semantic Scholar Table 2 from SRSF 5 : a novel marker for small-cell lung cancer and pleural metastatic cancer Short title : SRSF 5 protein is a new SCLC marker | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3eb8aeb3ef0e5fbd41ccaac4c356ef547e9dadef/22-Table2-1.png)
Table 2 from SRSF 5 : a novel marker for small-cell lung cancer and pleural metastatic cancer Short title : SRSF 5 protein is a new SCLC marker | Semantic Scholar
![Immunohistochemistry analysis of small cell lung cancer samples (SCLC).... | Download Scientific Diagram Immunohistochemistry analysis of small cell lung cancer samples (SCLC).... | Download Scientific Diagram](https://www.researchgate.net/publication/254262198/figure/fig3/AS:667661587464195@1536194335426/Immunohistochemistry-analysis-of-small-cell-lung-cancer-samples-SCLC-A.jpg)
Immunohistochemistry analysis of small cell lung cancer samples (SCLC).... | Download Scientific Diagram
![Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer - ScienceDirect Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169500216303099-gr1.gif)
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer - ScienceDirect
![Prognostic markers in lung cancer: is it ready for prime time? - Zhu - Translational Lung Cancer Research Prognostic markers in lung cancer: is it ready for prime time? - Zhu - Translational Lung Cancer Research](https://cdn.amegroups.cn/journals/pbpc/files/journals/5/articles/2729/public/2729-PB3-R1.png/w300)
Prognostic markers in lung cancer: is it ready for prime time? - Zhu - Translational Lung Cancer Research
![Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression | Scientific Reports Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-59031-1/MediaObjects/41598_2020_59031_Fig1_HTML.png)
Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression | Scientific Reports
![Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. | Semantic Scholar Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e7db51474405e7a96dad81cbfdf41e7c623abdb9/3-Table1-1.png)
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. | Semantic Scholar
![Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy - ScienceDirect Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1044579X17300974-gr2.jpg)